A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma

Conclusions AT-101 had no meaningful clinical activity in this study in patients with advanced ACC, but demonstrated feasibility of prospective therapeutic clinical trials in this rare cancer.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

This article summarizes the milestones in the development of camrelizumab leading to this first approval for classical Hodgkin lymphoma.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 11 July 2019Source: American Journal of Kidney DiseasesAuthor(s): Roman Shingarev, Ilya G. GlezermanImmunologic control of malignancy has long been recognized as an important determinant of disease progression. Recent advances in immunology have led to the focus on several mechanisms that can be targeted to achieve tumor suppression. In particular, checkpoint inhibition has evolved in less than a decade to become one of the most important strategies in cancer therapy, with a meaningful improvement in patient survival. Six agents have been approved for clinical use to date and many more ar...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Angiogenesis is the biological process by which new blood vessels are formed from pre-existing vessels. It is considered one of the classic hallmarks of cancer, as pathological angiogenesis provides oxygen and essential nutrients to growing tumors. Two of the seven known human oncoviruses, Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV), belong to the Gammaherpesvirinae subfamily. Both viruses are associated with several malignancies including lymphomas, nasopharyngeal carcinomas, and Kaposi’s sarcoma. The viral genomes code for a plethora of viral factors, including proteins and non...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
AbstractAimsOur aim was to investigate the glucose uptake in cancer patients suffering from different entities, using18F ‐FDG positron emission tomography–computed tomography scans. We further aimed at identifying potential variables altering cardiac and skeletal muscle glucose metabolism.Methods and resultsIn a retrospective cohort study, we analysed cardiac and skeletal muscle18F ‐FDG uptake in onco‐positron emission tomography–computed tomography scans in adult patients suffering from Hodgkin's lymphoma, non‐Hodgkin's lymphoma, and non‐lymphatic cancer including patients suffering from thyroid canc...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
The interaction between programmed cell death protein 1 (PD-1) receptor and their ligands programmed death-ligand 1 (PD-L1) induced exhaustions of cytotoxic lymphocytes in the tumor microenvironment, which facilitates tumor immune evasion. PD-1/PD-L1 blockade therapy, which prevents the receptors and ligands from binding to each other, disrupts the T-cell exhaustion signaling, thereby increases antitumor immunity. Inspiringly, it has revolutionized the treatment of many different types of cancers including non-small-cell lung carcinoma, melanoma, lymphoma, etc. However, with the intention of generating an anti-tumor immune...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Abstract Viruses and bacteria play central roles in gastrointestinal tumor development. This includes well-characterized contributions of Helicobacter pylori to gastric carcinoma and MALT lymphoma and of Hepatitis B and C virus infections to hepatocellular cancer. However, recent studies have demonstrated a much broader role of the microbiota in the regulation of cancer development. As such, it was shown that barrier defects and alterations in microbial community structure contribute to colorectal and hepatocellular cancer. Moreover, intriguing studies have highlighted the microbiota as a central regulator of the ...
Source: Zeitschrift fur Gastroenterologie - Category: Gastroenterology Authors: Tags: Z Gastroenterol Source Type: research
IL-35 is an immunosuppressive cytokine of the IL-12 family consisting of two subunits, EBV-induced gene 3 (EBI3) and p35. It has been shown to play a pro-tumor role in murine tumor models, and in various types of human cancer such as colorectal, pancreatic, or liver carcinoma, its expression has been associated with a worse clinical outcome. Here, we show by analyzing gene expression data from public databases and by immunohistochemical studies that IL-35 is overexpressed by tumor cells in diffuse-large B-cell lymphoma (DLBCL) compared to another type of mature aggressive B-cell lymphoma, Burkitt lymphoma. However, while h...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract Ferroptosis is a newly discovered form of iron-dependent oxidative cell death characterized by accumulating lipid-based reactive oxygen species (ROS) to a lethal level. It is distinct from other forms of cell death including apoptosis, necrosis and auto-phage in the aspects of morphology, biochemistry and genetics. Ferroptosis could be triggered by system xc- inhibitors or GHx4 inhibitors, as well as drugs such as sorafenib, SAS, and ART. Recently, studies have demonstrated that ferroptosis was critical in regulating tumor growth, such as hepatocellular carcinoma(HCC), renal cell carcinoma(RCC), non-small...
Source: Current Gene Therapy - Category: Genetics & Stem Cells Authors: Tags: Curr Gene Ther Source Type: research
ConclusionsAYA in the US experience disparities in cancer survival based on insurance status, independent of late stage of presentation. Patients age 26 ‐39 may be especially vulnerable to health outcomes associated with poor socioeconomic status, treatment disparities, and poor access to care.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conditions:   Malignancy;   Non-hodgkin Lymphoma;   Multiple Myeloma;   Breast Cancer;   Ovarian Cancer;   Soft Tissue Sarcoma;   Squamous Cell Carcinoma;   Head and Neck Cancer;   DLBCL;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Leiomyosarcoma;   Pancreatic Cancer;   Sarcom a;   CLL Intervention:   Drug: CYT-0851 Sponsor:   Cyteir Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Drugs & Pharmacology | Investigational New Drugs | Lymphoma | Study | Toxicology